A Two-part Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of Multiple Ascending Doses of AZD6738 in Patients With Prospectively Identified 11q-Deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), Prolymphocytic Leukaemia (PLL) or B Cell Lymphomas.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Ceralasertib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Lymphoid leukaemia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 18 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2016 to 1 May 2016.
- 03 Feb 2014 According to the ClinicalTrials.gov record, planned number of patients changed from 100 to 76.